Liver Drug Could Reverse Scarring, Mouse Study Finds
Adults with advanced liver scarring may one day benefit, as the drug is already in phase 3 human trials for other uses.
Updated on Nov. 7, 2026 in Weight Loss

Preclinical research in mice found that pegozafermin, a long-acting FGF21 analog already in phase 3 human trials, reversed liver fibrosis and showed signs of regressing established cirrhosis. The findings were presented at The Liver Meeting 2026 and are based on animal data only.
Why it matters
Cirrhosis and advanced scarring of the liver are hard to reverse, so a drug that appears to shrink established scarring in animals would be a notable shift if it held up in people. The research also measured hard endpoints, including cirrhosis and liver cancer, rather than only markers of inflammation.
This preclinical study used a diet-based mouse model, with treatment started only after animals reached advanced F3 fibrosis or F4 cirrhosis. Results in animals do not establish the same effect in people, and the cancer-prevention finding will require larger, longer studies to confirm.
The players
Beth Israel Deaconess Medical Center
A Harvard-affiliated teaching hospital whose researchers contribute to liver disease and metabolic research.
Zaur Abilov
A researcher affiliated with Beth Israel Deaconess Medical Center who contributed to this study of pegozafermin.
The details
Pegozafermin is a long-acting analog of FGF21, a hormone the liver naturally produces that helps regulate metabolism and inflammation. In the mouse experiments, the drug reduced collagen, the protein that builds scar tissue, to levels below where the animals started. The researchers also reported that it prevented liver cancer in the model, though that finding remains preliminary.
Timeline
Findings were presented at The Liver Meeting 2026.
Health Landscape
Fatty liver disease with advancing scarring has lacked therapies that reverse established fibrosis, and most treatments aim to slow progression. Pegozafermin already in phase 3 trials gives this preclinical signal a clearer path toward human testing if the results hold.
If you have fatty liver disease or known liver scarring, this preclinical work is an early signal rather than a change in care, so it is worth asking your doctor about current options. Anyone with known liver disease should keep up with recommended monitoring and discuss any new research with a clinician before drawing conclusions.
The takeaway
Results from mice do not predict human outcomes, but a drug that may reverse established liver scarring is a meaningful direction to watch. Ask your physician about liver health monitoring if you carry risk factors for fatty liver disease.
Further reading
For broader context on metabolic health, explore our Weight Loss coverage.
Source note: This article includes information reported by Ajmc.


